Breaking News

Tuesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Mesoblast completes $110M financing by strategic investor group » 07:51
03/02/21
03/02
07:51
03/02/21
07:51
MESO

Mesoblast

$9.60 /

+ (+0.00%)

Mesoblast Limited…

Mesoblast Limited announced it has entered into subscription agreements for a total of $110M via the issue of 60 million shares in a private placement led by a strategic US investor group, at A$2.30 per share, a 6.5% discount to the price at the close of trading February 25, 2021. Based on the US$110 million private placement, pro-forma cash-on-hand at December 31, 2020 would be approximately US$187.5 million. The investors also receive warrants to acquire a further 15 million shares at a price of A$2.88 per share, a 25% premium to the placement price, which may raise up to a further A$43.2 million, on or before 15 March 2028. Mesoblast has a right to call on the funds at any time during the term, subject to a share trading price of at least A$4.32 for 45 consecutive days. Specific use of proceeds includes: The private placement will provide financial strength for operational and regulatory initiatives across multiple products as the company undertakes important late-stage meetings with the United States Food & Drug Administration in the second and third quarters of this calendar year. Investment in commercial supply of remestemcel-L ahead of potential approval for graft versus host disease in children and in optimized manufacturing for larger market opportunities. Advancing manufacturing and development of rexlemestrocel-L platform to meet commercial objectives for chronic heart failure and chronic low back pain due to degenerative disc disease following the recent completion of Phase 3 trials in these indications. Working capital and general corporate purposes.

ShowHide Related Items >><<
MESO Mesoblast
$9.60 /

+ (+0.00%)

MESO Mesoblast
$9.60 /

+ (+0.00%)

02/11/21 Chardan
Mesoblast will need additional studies after Phase III miss, says Chardan
01/19/21 Jefferies
Mesoblast downgraded to Hold from Buy at Jefferies
12/22/20
Fly Intel: Top five analyst downgrades
12/22/20 Maxim
Mesoblast downgraded to Hold from Buy at Maxim
MESO Mesoblast
$9.60 /

+ (+0.00%)

MESO Mesoblast
$9.60 /

+ (+0.00%)

MESO Mesoblast
$9.60 /

+ (+0.00%)

Monday
Hot Stocks
Cerecor appoints Schond Greenway as CFO » 07:41
03/01/21
03/01
07:41
03/01/21
07:41
CERC

Cerecor

$3.38 /

-0.255 (-7.02%)

, MESO

Mesoblast

$9.60 /

+ (+0.00%)

Cerecor (CERC) announced…

Cerecor (CERC) announced the appointment of Schond Greenway as CFO, effective March 1, 2021. Chris Sullivan, who has served as the Company's Interim CFO for the past year, will continue with the Company as its CAO. Greenway joins Cerecor from Mesoblast (MESO), an allogeneic cellular medicines company, where he served as Vice President, Investor Relations. In connection with the appointment of Mr. Greenway and in accordance with the terms of his employment agreement with the Company, Cerecor's Board of Directors approved the grant to Mr. Greenway of a non-qualified stock option awarded to purchase 500,000 shares of its common stock, vesting over four years, with a twelve-month cliff, such that the first 25% will vest on the first anniversary following Mr. Greenway's start date with the Company, and the remainder will vest in equal monthly installments over the following three years, in each case, subject to continued employment with the Company through the applicable vesting date.

ShowHide Related Items >><<
MESO Mesoblast
$9.60 /

+ (+0.00%)

CERC Cerecor
$3.38 /

-0.255 (-7.02%)

CERC Cerecor
$3.38 /

-0.255 (-7.02%)

03/13/20
Fly Intel: Top five analyst downgrades
03/13/20 Maxim
Cerecor downgraded to Hold from Buy at Maxim
MESO Mesoblast
$9.60 /

+ (+0.00%)

02/11/21 Chardan
Mesoblast will need additional studies after Phase III miss, says Chardan
01/19/21 Jefferies
Mesoblast downgraded to Hold from Buy at Jefferies
12/22/20
Fly Intel: Top five analyst downgrades
12/22/20 Maxim
Mesoblast downgraded to Hold from Buy at Maxim
MESO Mesoblast
$9.60 /

+ (+0.00%)

  • 08
    Jan
  • 09
    Jun
MESO Mesoblast
$9.60 /

+ (+0.00%)

CERC Cerecor
$3.38 /

-0.255 (-7.02%)

MESO Mesoblast
$9.60 /

+ (+0.00%)

Over a week ago
Hot Stocks
Mesoblast trading halted, news pending  17:59
02/25/21
02/25
17:59
02/25/21
17:59
MESO

Mesoblast

$9.60 /

+0.1 (+1.05%)

 
ShowHide Related Items >><<
MESO Mesoblast
$9.60 /

+0.1 (+1.05%)

MESO Mesoblast
$9.60 /

+0.1 (+1.05%)

02/11/21 Chardan
Mesoblast will need additional studies after Phase III miss, says Chardan
01/19/21 Jefferies
Mesoblast downgraded to Hold from Buy at Jefferies
12/22/20
Fly Intel: Top five analyst downgrades
12/22/20 Maxim
Mesoblast downgraded to Hold from Buy at Maxim
MESO Mesoblast
$9.60 /

+0.1 (+1.05%)

MESO Mesoblast
$9.60 /

+0.1 (+1.05%)

MESO Mesoblast
$9.60 /

+0.1 (+1.05%)

Hot Stocks
Mesoblast's remestemcel-L candidate in MSC shows efficacy in publication » 06:11
02/17/21
02/17
06:11
02/17/21
06:11
MESO

Mesoblast

$10.24 /

-0.27 (-2.57%)

Mesoblast announced that…

Mesoblast announced that the Pediatrics Journal has published a paper on the first two children treated with Mesoblast's mesenchymal stromal cell - MSC - product candidate remestemcel-L for life-threatening multisystem inflammatory syndrome - or MIS-C- associated with COVID-19. MIS-C, a potentially life-threatening inflammatory condition, is associated with prior rather than active COVID-19 infection. It is thought to be a post-viral autoimmune process where the body's over-zealous reaction to the virus causes the damage. The two patients detailed in the paper were previously exposed to COVID-19 infection and later developed MIS-C. When treated with two intravenous doses of remestemcel-L separated by 48 hours, normalization of left ventricular ejection fraction, notable reductions in biomarkers of systemic and cardiac inflammation, and improved clinical status occurred. There were no safety signals associated with the remestemcel-L treatment. Both patients were subsequently discharged from hospital.

ShowHide Related Items >><<
MESO Mesoblast
$10.24 /

-0.27 (-2.57%)

MESO Mesoblast
$10.24 /

-0.27 (-2.57%)

02/11/21 Chardan
Mesoblast will need additional studies after Phase III miss, says Chardan
01/19/21 Jefferies
Mesoblast downgraded to Hold from Buy at Jefferies
12/22/20
Fly Intel: Top five analyst downgrades
12/22/20 Maxim
Mesoblast downgraded to Hold from Buy at Maxim
MESO Mesoblast
$10.24 /

-0.27 (-2.57%)

MESO Mesoblast
$10.24 /

-0.27 (-2.57%)

MESO Mesoblast
$10.24 /

-0.27 (-2.57%)

Recommendations
Mesoblast will need additional studies after Phase III miss, says Chardan » 07:58
02/11/21
02/11
07:58
02/11/21
07:58
MESO

Mesoblast

$9.90 /

-0.17 (-1.69%)

Chardan analyst Keay…

Chardan analyst Keay Nakae keeps a Sell rating on Mesoblast with a $7.50 price target after the Phase III study evaluating its rexlemestrocel-L mesenchymal precursor cell immunotherapy as a treatment for patients with chronic low back pain due to degenerative disc disease failed to achieve its primary efficacy endpoint. The analyst is "skeptical" that these results will prove to be sufficient to obtain an accelerated approval, due to the lack of concordance of the data from both this study and the prior Phase II study. Nakae believes Mesoblast will be required to conduct new Phase III studies in order to obtain FDA approval. The analyst sees an unfavorable risk/reward profile at the current stock levels.

ShowHide Related Items >><<
MESO Mesoblast
$9.90 /

-0.17 (-1.69%)

MESO Mesoblast
$9.90 /

-0.17 (-1.69%)

01/19/21 Jefferies
Mesoblast downgraded to Hold from Buy at Jefferies
12/22/20
Fly Intel: Top five analyst downgrades
12/22/20 Maxim
Mesoblast downgraded to Hold from Buy at Maxim
12/18/20 H.C. Wainwright
Mesoblast price target lowered to $16 from $20 at H.C. Wainwright
MESO Mesoblast
$9.90 /

-0.17 (-1.69%)

MESO Mesoblast
$9.90 /

-0.17 (-1.69%)

MESO Mesoblast
$9.90 /

-0.17 (-1.69%)

Hot Stocks
Mesoblast's chronic back pain therapy shows efficacy and opioid use reduction » 18:49
02/10/21
02/10
18:49
02/10/21
18:49
MESO

Mesoblast

$9.90 /

-0.17 (-1.69%)

Mesoblast announced…

Mesoblast announced results from the Phase 3 randomized controlled trial of its allogeneic mesenchymal precursor cell - MPC - therapy rexlemestrocel-L in 404 enrolled patients with chronic low back pain due to degenerative disc disease refractory to conventional treatments. Results indicate that a single injection of rexlemestrocel-L may provide a safe, durable, and effective opioid-sparing therapy for patients with chronic inflammatory back pain due to degenerative disc disease, and that greatest benefits are seen when administered earlier in the disease process. A single injection of MPC + Hyaluronic Acid (HA) carrier resulted in significant and durable reductions in CLBP through 24 months across the entire evaluable study population; significantly greater pain reduction in the patient subset of opioid users; increased composite outcomes of reduction in pain together with improvement in function in those with CLBP of shorter duration than 68 months; however, the composite outcomes of pain and function did not reach statistical significance across the entire study. No safety concerns over the 24-month period of follow-up in the entire study population. Mesoblast will meet with the FDA to discuss the results from this trial together with the earlier trial of MPC + HA, and potential approval pathways for rexlemestrocel-L + HA as treatment for durable reduction in CLBP due to DDD with opioid sparing activity.

ShowHide Related Items >><<
MESO Mesoblast
$9.90 /

-0.17 (-1.69%)

MESO Mesoblast
$9.90 /

-0.17 (-1.69%)

01/19/21 Jefferies
Mesoblast downgraded to Hold from Buy at Jefferies
12/22/20
Fly Intel: Top five analyst downgrades
12/22/20 Maxim
Mesoblast downgraded to Hold from Buy at Maxim
12/18/20 H.C. Wainwright
Mesoblast price target lowered to $16 from $20 at H.C. Wainwright
MESO Mesoblast
$9.90 /

-0.17 (-1.69%)

MESO Mesoblast
$9.90 /

-0.17 (-1.69%)

MESO Mesoblast
$9.90 /

-0.17 (-1.69%)

Options
Largest borrow rate increases among liquid names » 08:45
02/08/21
02/08
08:45
02/08/21
08:45
FTEK

Fuel Tech

$5.15 /

-0.02 (-0.39%)

, SRE

Sempra Energy

$126.35 /

+0.29 (+0.23%)

, MESO

Mesoblast

$9.69 /

+0.2 (+2.11%)

, ACTC

ArcLight Clean Transition

$24.88 /

-0.31 (-1.23%)

, API

Agora

$98.99 /

+10.98 (+12.48%)

, BTBT

Bit Digital

$17.39 /

-1.56 (-8.23%)

, ENB

Enbridge

$35.15 /

-0.125 (-0.35%)

, BLDP

Ballard Power

$38.65 /

+0.49 (+1.28%)

, LODE

Comstock Mining

$1.74 /

+0.02 (+1.16%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Fuel Tech (FTEK) 34.72% +6.29, Sempra Energy (SRE) 1.15% +0.90, Mesoblast (MESO) 80.65% +0.58, ArcLight Clean Transition Corp (ACTC) 8.61% +0.56, Agora (API) 3.22% +0.48, Direxion Daily Semiconductor Bear 3X Shares (SOXS) 8.31% +0.48, Bit Digital (BTBT) 38.68% +0.44, Enbridge (ENB) 0.69% +0.35, Ballard Power (BLDP) 0.74% +0.33, and Comstock Mining (LODE) 12.52% +0.28.

ShowHide Related Items >><<
SRE Sempra Energy
$126.35 /

+0.29 (+0.23%)

MESO Mesoblast
$9.69 /

+0.2 (+2.11%)

LODE Comstock Mining
$1.74 /

+0.02 (+1.16%)

FTEK Fuel Tech
$5.15 /

-0.02 (-0.39%)

ENB Enbridge
$35.15 /

-0.125 (-0.35%)

BTBT Bit Digital
$17.39 /

-1.56 (-8.23%)

BLDP Ballard Power
$38.65 /

+0.49 (+1.28%)

API Agora
$98.99 /

+10.98 (+12.48%)

ACTC ArcLight Clean Transition
$24.88 /

-0.31 (-1.23%)

FTEK Fuel Tech
$5.15 /

-0.02 (-0.39%)

03/13/20 H.C. Wainwright
Fuel Tech downgraded to Neutral from Buy at H.C. Wainwright
SRE Sempra Energy
$126.35 /

+0.29 (+0.23%)

01/14/21 Wells Fargo
Sempra Energy upgraded to Overweight from Equal Weight at Wells Fargo
01/14/21 Wells Fargo
Sempra Energy upgraded to Overweight from Equal Weight at Wells Fargo
01/05/21 Barclays
Sempra Energy price target lowered to $149 from $159 at Barclays
12/16/20 Mizuho
Sempra Energy price target raised to $137 from $119 at Mizuho
MESO Mesoblast
$9.69 /

+0.2 (+2.11%)

01/19/21 Jefferies
Mesoblast downgraded to Hold from Buy at Jefferies
12/22/20
Fly Intel: Top five analyst downgrades
12/22/20 Maxim
Mesoblast downgraded to Hold from Buy at Maxim
12/18/20 H.C. Wainwright
Mesoblast price target lowered to $16 from $20 at H.C. Wainwright
ACTC ArcLight Clean Transition
$24.88 /

-0.31 (-1.23%)

API Agora
$98.99 /

+10.98 (+12.48%)

01/05/21 China Renaissance
Agora initiated with a Buy at China Renaissance
11/17/20 Needham
Agora price target lowered to $50 from $55 at Needham
11/02/20 86 Research
Agora initiated with a Buy at 86 Research
08/18/20 Needham
Agora price target lowered to $55 from $60 at Needham
BTBT Bit Digital
$17.39 /

-1.56 (-8.23%)

ENB Enbridge
$35.15 /

-0.125 (-0.35%)

01/27/21 National Bank
Enbridge price target lowered to C$52 from C$54 at National Bank
01/13/21 CIBC
Enbridge price target raised to C$53 from C$47 at CIBC
01/04/21 Citi
Citi now prefers TC Energy over Enbridge, still likes both
12/10/20 National Bank
Enbridge price target lowered to C$54 from C$55 at National Bank
BLDP Ballard Power
$38.65 /

+0.49 (+1.28%)

02/01/21 CIBC
Ballard Power initiated with a Neutral at CIBC
01/27/21 Piper Sandler
Ballard Power initiated with a Neutral at Piper Sandler
01/20/21 Citi
Ballard Power initiated with a Buy at Citi
01/19/21 BMO Capital
Ballard Power initiated with an Outperform at BMO Capital
LODE Comstock Mining
$1.74 /

+0.02 (+1.16%)

07/22/20 Noble Capital
Comstock Mining initiated with an Outperform at Noble Capital
SRE Sempra Energy
$126.35 /

+0.29 (+0.23%)

MESO Mesoblast
$9.69 /

+0.2 (+2.11%)

FTEK Fuel Tech
$5.15 /

-0.02 (-0.39%)

ENB Enbridge
$35.15 /

-0.125 (-0.35%)

BLDP Ballard Power
$38.65 /

+0.49 (+1.28%)

API Agora
$98.99 /

+10.98 (+12.48%)

  • 24
    Nov
  • 26
    Jun
ENB Enbridge
$35.15 /

-0.125 (-0.35%)

BTBT Bit Digital
$17.39 /

-1.56 (-8.23%)

ACTC ArcLight Clean Transition
$24.88 /

-0.31 (-1.23%)

MESO Mesoblast
$9.69 /

+0.2 (+2.11%)

BTBT Bit Digital
$17.39 /

-1.56 (-8.23%)

BLDP Ballard Power
$38.65 /

+0.49 (+1.28%)

API Agora
$98.99 /

+10.98 (+12.48%)

SRE Sempra Energy
$126.35 /

+0.29 (+0.23%)

MESO Mesoblast
$9.69 /

+0.2 (+2.11%)

LODE Comstock Mining
$1.74 /

+0.02 (+1.16%)

FTEK Fuel Tech
$5.15 /

-0.02 (-0.39%)

ENB Enbridge
$35.15 /

-0.125 (-0.35%)

BTBT Bit Digital
$17.39 /

-1.56 (-8.23%)

BLDP Ballard Power
$38.65 /

+0.49 (+1.28%)

API Agora
$98.99 /

+10.98 (+12.48%)

ACTC ArcLight Clean Transition
$24.88 /

-0.31 (-1.23%)

Over a month ago
Options
Largest borrow rate increases among liquid names » 08:45
01/29/21
01/29
08:45
01/29/21
08:45
FIZZ

National Beverage

$157.25 /

-24.28 (-13.38%)

, VTNR

Vertex Energy

$1.84 /

-0.25 (-11.96%)

, FTEK

Fuel Tech

$5.16 /

-0.29 (-5.32%)

, VNTR

Venator Materials

$4.20 /

+0.18 (+4.48%)

, LGVW

Longview Acquisition Corp.

$17.93 /

+0.92 (+5.41%)

, QTT

Qutoutiao

$3.22 /

-0.21 (-6.12%)

, MESO

Mesoblast

$9.23 /

+0.32 (+3.59%)

, DRIV

Digital River

$26.66 /

-0.23 (-0.86%)

, SRE

Sempra Energy

$124.74 /

+4.93 (+4.11%)

, REV

Revlon

$12.05 /

-5.41 (-30.99%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: National Beverage (FIZZ) 3.14% +1.21, Sempra Energy (SRE) 1.19% +0.94, Global X Autonomous and Electric Vehicles ETF (DRIV) 17.72% +0.94, Mesoblast (MESO) 82.79% +0.84, Qutoutiao (QTT) 15.24% +0.63, Longview Acquisition Corp (LGVW) 8.68% +0.49, Venator Materials (VNTR) 4.63% +0.42, Fuel Tech (FTEK) 33.08% +0.40, Vertex Energy (VTNR) 3.01% +0.39, and Revlon (REV) 45.52% +0.30.

ShowHide Related Items >><<
VTNR Vertex Energy
$1.84 /

-0.25 (-11.96%)

VNTR Venator Materials
$4.20 /

+0.18 (+4.48%)

SRE Sempra Energy
$124.74 /

+4.93 (+4.11%)

REV Revlon
$12.05 /

-5.41 (-30.99%)

MESO Mesoblast
$9.23 /

+0.32 (+3.59%)

LGVW Longview Acquisition Corp.
$17.93 /

+0.92 (+5.41%)

FTEK Fuel Tech
$5.16 /

-0.29 (-5.32%)

FIZZ National Beverage
$157.25 /

-24.28 (-13.38%)

FIZZ National Beverage
$157.25 /

-24.28 (-13.38%)

10/20/20
Fly Intel: Top five analyst upgrades
10/20/20 Jefferies
National Beverage upgraded to Hold on better La Croix market share at Jefferies
10/20/20 Jefferies
National Beverage upgraded to Hold from Underperform at Jefferies
05/18/20 Guggenheim
National Beverage price target raised to $38 from $34 at Guggenheim
VTNR Vertex Energy
$1.84 /

-0.25 (-11.96%)

FTEK Fuel Tech
$5.16 /

-0.29 (-5.32%)

03/13/20 H.C. Wainwright
Fuel Tech downgraded to Neutral from Buy at H.C. Wainwright
VNTR Venator Materials
$4.20 /

+0.18 (+4.48%)

11/30/20 BofA
Venator Materials upgraded to Buy from Underperform at BofA
04/21/20 BMO Capital
Venator Materials downgraded to Market Perform from Outperform at BMO Capital
04/08/20 Citi
Venator Materials price target lowered to $1.40 from $2.30 at Citi
03/30/20 Goldman Sachs
Venator Materials downgraded to Neutral from Buy at Goldman Sachs
LGVW Longview Acquisition Corp.
$17.93 /

+0.92 (+5.41%)

QTT Qutoutiao
$3.22 /

-0.21 (-6.12%)

MESO Mesoblast
$9.23 /

+0.32 (+3.59%)

01/19/21 Jefferies
Mesoblast downgraded to Hold from Buy at Jefferies
12/22/20
Fly Intel: Top five analyst downgrades
12/22/20 Maxim
Mesoblast downgraded to Hold from Buy at Maxim
12/18/20 H.C. Wainwright
Mesoblast price target lowered to $16 from $20 at H.C. Wainwright
DRIV Digital River
$26.66 /

-0.23 (-0.86%)

SRE Sempra Energy
$124.74 /

+4.93 (+4.11%)

01/14/21 Wells Fargo
Sempra Energy upgraded to Overweight from Equal Weight at Wells Fargo
01/14/21 Wells Fargo
Sempra Energy upgraded to Overweight from Equal Weight at Wells Fargo
01/05/21 Barclays
Sempra Energy price target lowered to $149 from $159 at Barclays
12/16/20 Mizuho
Sempra Energy price target raised to $137 from $119 at Mizuho
REV Revlon
$12.05 /

-5.41 (-30.99%)

03/11/20 Jefferies
Estee Lauder, Coty, L'Oreal price targets lowered at Jefferies
VTNR Vertex Energy
$1.84 /

-0.25 (-11.96%)

VNTR Venator Materials
$4.20 /

+0.18 (+4.48%)

SRE Sempra Energy
$124.74 /

+4.93 (+4.11%)

REV Revlon
$12.05 /

-5.41 (-30.99%)

QTT Qutoutiao
$3.22 /

-0.21 (-6.12%)

MESO Mesoblast
$9.23 /

+0.32 (+3.59%)

FTEK Fuel Tech
$5.16 /

-0.29 (-5.32%)

FIZZ National Beverage
$157.25 /

-24.28 (-13.38%)

REV Revlon
$12.05 /

-5.41 (-30.99%)

FIZZ National Beverage
$157.25 /

-24.28 (-13.38%)

VNTR Venator Materials
$4.20 /

+0.18 (+4.48%)

REV Revlon
$12.05 /

-5.41 (-30.99%)

QTT Qutoutiao
$3.22 /

-0.21 (-6.12%)

MESO Mesoblast
$9.23 /

+0.32 (+3.59%)

LGVW Longview Acquisition Corp.
$17.93 /

+0.92 (+5.41%)

FIZZ National Beverage
$157.25 /

-24.28 (-13.38%)

SRE Sempra Energy
$124.74 /

+4.93 (+4.11%)

REV Revlon
$12.05 /

-5.41 (-30.99%)

QTT Qutoutiao
$3.22 /

-0.21 (-6.12%)

MESO Mesoblast
$9.23 /

+0.32 (+3.59%)

LGVW Longview Acquisition Corp.
$17.93 /

+0.92 (+5.41%)

FTEK Fuel Tech
$5.16 /

-0.29 (-5.32%)

FIZZ National Beverage
$157.25 /

-24.28 (-13.38%)

DRIV Digital River
$26.66 /

-0.23 (-0.86%)

Conference/Events
Mesoblast participates in a conference call with Cantor Fitzgerald » 07:55
01/20/21
01/20
07:55
01/20/21
07:55
MESO

Mesoblast

$9.39 /

-0.3 (-3.10%)

Biopharma Analyst Chen…

Biopharma Analyst Chen holds a conference call with CEO Itescu and CFO Muntner who will discuss the 2021 outlook and next steps going forward for the pipeline on January 20 at 8 am hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
MESO Mesoblast
$9.39 /

-0.3 (-3.10%)

MESO Mesoblast
$9.39 /

-0.3 (-3.10%)

01/19/21 Jefferies
Mesoblast downgraded to Hold from Buy at Jefferies
12/22/20
Fly Intel: Top five analyst downgrades
12/22/20 Maxim
Mesoblast downgraded to Hold from Buy at Maxim
12/18/20 H.C. Wainwright
Mesoblast price target lowered to $16 from $20 at H.C. Wainwright
MESO Mesoblast
$9.39 /

-0.3 (-3.10%)

MESO Mesoblast
$9.39 /

-0.3 (-3.10%)

MESO Mesoblast
$9.39 /

-0.3 (-3.10%)

Conference/Events
Mesoblast participates in a conference call with Cantor Fitzgerald » 04:55
01/20/21
01/20
04:55
01/20/21
04:55
MESO

Mesoblast

$9.39 /

-0.3 (-3.10%)

Biopharma Analyst Chen…

Biopharma Analyst Chen holds a conference call with CEO Itescu and CFO Muntner who will discuss the 2021 outlook and next steps going forward for the pipeline on January 20 at 8 am hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
MESO Mesoblast
$9.39 /

-0.3 (-3.10%)

MESO Mesoblast
$9.39 /

-0.3 (-3.10%)

01/19/21 Jefferies
Mesoblast downgraded to Hold from Buy at Jefferies
12/22/20
Fly Intel: Top five analyst downgrades
12/22/20 Maxim
Mesoblast downgraded to Hold from Buy at Maxim
12/18/20 H.C. Wainwright
Mesoblast price target lowered to $16 from $20 at H.C. Wainwright
MESO Mesoblast
$9.39 /

-0.3 (-3.10%)

MESO Mesoblast
$9.39 /

-0.3 (-3.10%)

MESO Mesoblast
$9.39 /

-0.3 (-3.10%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.